Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Crinetics Pharmaceuticals Inc.
Grupo Espanol de Tumores Neuroendocrinos
Novartis
Hoffmann-La Roche
University Hospital, Rouen
Intergroupe Francophone de Cancerologie Thoracique
University of Alberta
Advanced Accelerator Applications
RayzeBio, Inc.
Rezolute